KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Effectiveness of self-abdominal massage on gastrointestinal function in postoperative ileus: a randomised controlled trial protocol. PMID 41688115 · BMJ Open · 2026-Feb-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A randomised trial of a bioreactor-produced EV-A71 vaccine for endemic control in children. PMID 41680199 · NPJ Vaccines · 2026-Feb-12 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fibrin sealant for prophylaxis of cervical anastomotic leakage after McKeown esophagectomy for esophageal or esophagogastric junction cancer (PLACE030): a Phase III multicenter randomized clinical trial. PMID 41677267 · Int J Surg · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the Phase 3 GRAVITI study. PMID 41674029 · Intest Res · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium. PMID 41347825 · Blood · 2026-Feb-12 The record describes a secondary prognostic study on time-to-relapse in T-cell lymphoma, using data from cohorts that include a randomized trial, but it is not the original formal-result report of a Phase III or II/III randomized trial of a drug intervention. The trial phase is not explicitly confirmed as Phase III/II in the metadata or abstract, and the report type is a secondary analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial. PMID 41211929 · N Engl J Med · 2026-Feb-12 The study is a Phase 3 randomized trial of a drug (sibeprenlimab) in IgA nephropathy, a non-oncologic condition. The primary endpoint is a change in urinary protein-to-creatinine ratio at 9 months, which is a surrogate biomarker/proteinuria outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the core eligibility criteria for the oncology Kaplan-Meier digitization cohort.
H L
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. PMID 41196369 · N Engl J Med · 2026-Feb-12 The study is a Phase III randomized controlled trial of a drug (atacicept) with results, but it is not an oncology study; it focuses on IgA nephropathy. Therefore, it does not meet the primary eligibility criterion of being for human malignant neoplasm.
H L
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia. PMID 41060318 · Blood · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Memantine to preserve memory and neurocognition following craniospinal irradiation (MEMENTO): a phase 3 randomized controlled trial. PMID 41673604 · BMC Cancer · 2026-Feb-11 This is a protocol for a Phase III randomized controlled trial evaluating memantine in patients receiving craniospinal irradiation for brain tumors. While it meets criteria for oncology, human subjects, randomization, Phase III, and drug intervention, it does not present original results with a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The abstract explicitly describes the trial design and planned endpoints but reports no efficacy outcomes. The publication type includes 'Clinical Trial, Phase III' and 'Randomized Controlled Trial,' but the content is a protocol registration, not a results report.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells. PMID 41673235 · Sci Rep · 2026-Feb-11 The record describes a preclinical study in cell lines comparing different radiosensitizing approaches. While it mentions a Phase 3 trial (TrilynX), the study itself is not a report of that trial's results. It is a laboratory investigation, not a clinical trial result report, and does not present a time-to-event efficacy endpoint (OS, PFS, etc.) from a human trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study. PMID 41670439 · Arthritis Rheumatol · 2026-Feb-11 The study is a Phase 3 randomized, placebo-controlled trial of guselkumab (a drug intervention) in human patients with psoriatic arthritis. However, it is not an oncology study (psoriatic arthritis is a rheumatologic condition), and the reported efficacy endpoints are clinical response measures (ACR20, PASI90, etc.), not time-to-event outcomes (e.g., OS, PFS, DFS, EFS, RFS, TTP) analyzed via Kaplan-Meier or hazard ratios. Therefore, it does not meet the oncology or time-to-event criteria for inclusion.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. PMID 41667119 · Eur Heart J · 2026-Feb-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Advances in Immunotherapy for Breast Cancer. PMID 41701864 · Oncology (Williston Park) · 2026-Feb-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A). PMID 41668051 · BMC Cancer · 2026-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Predictors of Efficacy Maintenance After Vunakizumab Discontinuation in Patients With Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of a Randomized Controlled Trial. PMID 41665599 · Int J Dermatol · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Spinal Manipulation and Clinician-Supported Biopsychosocial Self-Management for Acute Back Pain: The PACBACK Randomized Clinical Trial. PMID 41460638 · JAMA · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Targeted Oxygen for Initial Resuscitation of Preterm Infants: The TORPIDO 30/60 Randomized Clinical Trial. PMID 41369162 · JAMA · 2026-Feb-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. PMID 41143759 · J Am Coll Cardiol · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
FLT3-ITD measurable residual disease from the QuANTUM-First trial. PMID 41052406 · Blood Adv · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Role of melatonin for prevention of necrotizing enterocolitis in preterm infants: a randomized controlled trial. PMID 41847903 · J Trop Pediatr · 2026-Feb-09 The study is a randomized controlled trial in humans with a drug intervention (melatonin) and reports original results, but it is not an oncology study. It focuses on a neonatal condition (necrotizing enterocolitis), which is outside the scope of the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ESO annual stroke evidence update 2025. PMID 41706824 · Eur Stroke J · 2026-Feb-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification. PMID 40991667 · Clin Infect Dis · 2026-Feb-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. PMID 40694627 · Clin Infect Dis · 2026-Feb-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine. PMID 39879629 · Clin Infect Dis · 2026-Feb-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of an educational intervention model on pesticide practices among farmers: a randomized controlled trial protocol. PMID 41654733 · BMC Public Health · 2026-Feb-07 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma. PMID 41654611 · Sci Rep · 2026-Feb-07 The trial is explicitly described as a 'pilot study' and does not meet the phase requirement (Phase III/IIIb or Phase II/III). While it is randomized, has drug intervention, and reports time-to-event efficacy endpoints, the lack of definitive Phase II/III or Phase III evidence makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. PMID 41654375 · Lancet · 2026-Feb-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. PMID 41654374 · Lancet · 2026-Feb-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials. PMID 41651961 · Sci Rep · 2026-Feb-07 The record is a secondary analysis (journal article) of data from three separate Phase III trials, not the original formal report of a single randomized trial. It investigates associations between baseline cardiovascular medication use and outcomes, which is a post-hoc or secondary analysis, not the primary trial result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53). PMID 41796475 · Int J Gynecol Cancer · 2026-Feb-06 The record is a protocol for a planned randomized controlled trial comparing surgical techniques. It does not report results from a completed trial. Furthermore, the intervention is surgical, not drug-containing. The explicit trial phase is not stated in the provided metadata (though 'phase3_or_definitive' is null, the lack of explicit Phase III/IIIb designation and the absence of results are primary exclusions).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial. PMID 41651834 · Nat Commun · 2026-Feb-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study. PMID 41649965 · J Neuromuscul Dis · 2026-Feb-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity, safety, and lot consistency of the anthrax vaccine adsorbed, adjuvanted for post-exposure prophylaxis of anthrax in healthy adults: A phase 3, randomized, double-blind trial. PMID 41401704 · Vaccine · 2026-Feb-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. PMID 41879224 · N Engl J Med · 2026-Feb-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Does the Fissure Last Technique Really Reduce Postoperative Airleak After Lung Resection? Results From a Prospective Randomized Controlled Trial. PMID 41689184 · Interdiscip Cardiovasc Thorac Surg · 2026-Feb-05 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Feasibility of a phase 3 partially randomised clinical trial to assess the safety and efficacy of paediatric praziquantel for schistosomiasis treatment in children aged 3 months to 6 years in endemic regions of Brazil: a pilot study. PMID 41644160 · BMJ Open · 2026-Feb-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial. PMID 41644158 · BMJ Open · 2026-Feb-05 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A descriptive comparison of phase 3 results and head-to-head trials in inflammatory bowel diseases. PMID 41609414 · J Crohns Colitis · 2026-Feb-05 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial. PMID 41572426 · Oncologist · 2026-Feb-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Triplet chemotherapy combined with anti Epidermal Growth Factor Receptor treatment in RAS wild-type colorectal cancer: a network metanalysis. PMID 41537260 · Oncologist · 2026-Feb-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer. PMID 41537257 · Oncologist · 2026-Feb-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial. PMID 41520166 · Oncologist · 2026-Feb-05 The study is a Phase III randomized trial in oncology with a drug intervention, but its primary efficacy endpoint (complete response rate) is a binary outcome, not a time-to-event endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the time-to-event criterion for inclusion in a Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Somapacitan in children with idiopathic short stature: a randomized controlled phase 3 study. PMID 41712606 · Eur J Endocrinol · 2026-Feb-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Plant-based whole-food diets are feasible during autologous stem cell transplantation and are associated with dose-dependent microbiome modulation: Results from a pilot clinical trial. PMID 41674628 · medRxiv · 2026-Feb-04 The study is a single-arm, pilot trial in multiple myeloma patients, focusing on a dietary (plant-based food) intervention, not a drug. It lacks a randomized control arm, is not a Phase III/IIIb or Phase II/III trial, and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The primary endpoints are feasibility and tolerability, with secondary microbiome endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recombinant human growth hormone (rHGH) for muscle enhancement in knee osteoarthritis: protocol for a pilot, randomised placebo-controlled trial. PMID 41638751 · BMJ Open · 2026-Feb-04 方案论文未报告临床试验结果。
H L
旧查询独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study. PMID 41632483 · Rheumatology (Oxford) · 2026-Feb-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer. PMID 41324553 · Clin Cancer Res · 2026-Feb-04 The record describes a secondary analysis/methodological paper developing a prediction model using data from two Phase III randomized trials. While it is an original result in terms of the model, it is not the primary report of the drug trial efficacy results. The specific drug intervention (e.g., abiraterone for COU-AA-302) is not explicitly mentioned or the focus of this report, so drug intervention cannot be established from the abstract. Therefore, it does not meet all required criteria for inclusion in the drug-intervention KM digitization cohort.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer. PMID 41174882 · Mol Ther · 2026-Feb-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study. PMID 40577173 · Clin Infect Dis · 2026-Feb-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years. PMID 40464662 · Clin Infect Dis · 2026-Feb-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -